Related Experiment Video

Updated: Jun 8, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Everolimus in renal cell carcinoma

Y Wang1

  • 1International Biomedical Communications, Frederick, MD, USA. Dr.Yanni.Wang@gmail.com

Drugs of Today (Barcelona, Spain : 1998)
|September 11, 2010
PubMed

Insights

Everolimus (RAD-001) is an effective treatment for advanced renal cell carcinoma (RCC) that has progressed on other therapies. This oral medication demonstrated good tolerability and improved progression-free survival rates in patients with advanced RCC.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced renal cell carcinoma (RCC) presents a significant therapeutic challenge.
  • Prior treatments like sunitinib and sorafenib may not be effective for all patients.
  • Mammalian target of rapamycin (mTOR) pathway inhibitors offer a novel therapeutic approach.

Purpose of the Study:

  • To evaluate the efficacy and safety of everolimus in patients with advanced RCC.
  • To determine the progression-free survival (PFS) rates associated with everolimus treatment.
  • To identify the most common adverse events in patients receiving everolimus.

Main Methods:

  • A randomized phase III clinical trial was conducted.
  • Patients received 10 mg of everolimus daily.
  • Disease progression was assessed based on predefined criteria.

Main Results:

  • Everolimus demonstrated a 36% 6-month PFS rate and a 31% 3-month PFS rate.
  • The treatment was generally well-tolerated, with most adverse events being mild to moderate.
  • Frequent grade 3-4 adverse events included stomatitis, fatigue, pneumonitis, and infections.

Conclusions:

  • Everolimus is an effective and well-tolerated treatment option for advanced RCC patients progressing on prior therapies.
  • The drug offers a meaningful improvement in progression-free survival.
  • Ongoing trials are exploring combination therapies involving everolimus for RCC treatment.

More Related Videos

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts07:50

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts

Published on: May 25, 2018

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...